Cardiothoracic & vascular anesthesia
Effect of High-Dose Selenium on Postoperative Organ Dysfunction and Mortality in Cardiac Surgery Patients: The SUSTAIN CSX Randomized Clinical Trial
Authors' conclusion
In high-risk cardiac surgery patients, perioperative administration of high-dose intravenous sodium selenite did not reduce morbidity or mortality.
Study context
- Population
- Adult cardiac surgery patients with EuroSCORE II-predicted mortality ≥5% or planned combined procedures, 23 sites in Germany and Canada, 2015–2021analysed
- Participants
- 1,416 patients
- Comparison
- Perioperative high-dose IV sodium selenite vs placebo
- Primary endpoint
- Composite of:
- Days alive
- Free from organ dysfunction
- Follow-up
- First 30 days after cardiac surgery
Methodological detailsmulticentre, double-blind, placebo-controlled
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
P = 0.45
Further findings
| Outcome | Selenium | Placebo | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| 30-day mortality | 4.2% | 5.0% | 0.82 (0.50–1.36) | P = 0.44 | |
| 0.512Odds ratio (log scale) |
Safety
Safety outcomes
- Did not differ between the groups
Original publication
Effect of High-Dose Selenium on Postoperative Organ Dysfunction and Mortality in Cardiac Surgery Patients: The SUSTAIN CSX Randomized Clinical Trial. JAMA Surg. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →